Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
Waldenstrom macroglobulinemia (WM) is a type of incurable, indolent B-cell lymphoma that is prone to relapse. Over time, treatment strategies have progressed from cytotoxic drugs to rituximab (R)- or bortezomib (V)-based regimens, and have now entered into an era of Bruton tyrosine kinase inhibitor...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer Health
2024-01-01
|
| Serie: | Blood Science |
| Accesso online: | http://journals.lww.com/10.1097/BS9.0000000000000179 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|